AKBA - Company ID 0001517022
The table below shows Akebia Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$21.21M | -$13.59M | -$19.43M | -$17.54M | -$21.62M | -$70.75M |
| Capital expenditure | $62.00K | $18.00K | $0.00 | $0.00 | $114.00K | $59.00K |
| Investing cash flow | -$62.00K | $154.00K | $0.00 | $0.00 | -$114.00K | $19.94M |
| Dividends paid | - | - | - | - |
Akebia Therapeutics, Inc. reported operating cash flow of $67.99M for fiscal year 2025. That is up 267.2% from -$40.66M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $57.91M (FY 2016) to $67.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$926.00K | $74.94M | $18.48M | -$15.97M | $47.55M | $74.48M |